Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1,897 INR | +0.38% |
|
+7.30% | +16.75% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's high margin levels account for strong profits.
- The company is in a robust financial situation considering its net cash and margin position.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The opinion of analysts covering the stock has improved over the past four months.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- With an expected P/E ratio at 49.03 and 41.95 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+16.75% | 3.51B | C- | ||
+48.79% | 781B | C+ | ||
+41.68% | 639B | B | ||
+19.43% | 330B | B- | ||
+7.18% | 293B | C+ | ||
+17.81% | 248B | B+ | ||
+0.25% | 221B | A+ | ||
+11.65% | 217B | B- | ||
+4.53% | 162B | C+ | ||
-3.92% | 157B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- JBCHEPHARM Stock
- Ratings J. B. Chemicals & Pharmaceuticals Limited